Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.44 |
| ▸ | BCL9 | O00512 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181736 | 0.94 | KCNH2 (0.57) | KCNH2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL16682352 | 0.88 | KCNH2 (0.60) | KCNH2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL30849521 | 0.86 | KCNH2 (0.50) | KCNH2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL6247395 | 0.83 | KCNH2 (0.56) | KCNH2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL6181840 | 0.83 | CA12 (0.40) | KCNH2ALDH1A1 | |
| SCHEMBL12925089 | 0.82 | KCNH2 (0.55) | KCNH2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL25718431 | 0.82 | KCNH2 (0.54) | KCNH2MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL991681 | 0.81 | KCNH2 (0.54) | KCNH2MAPTACHESLC6A4PPARD | |
| SCHEMBL16682345 | 0.81 | KCNH2 (0.73) | KCNH2MAPTALDH1A1PPARD | |
| SCHEMBL4496249 | 0.80 | KCNH2 (0.51) | KCNH2MAPTCRHBPCRHR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507530-B1 | DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-1507530-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6818663-B2 | AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS | HOFFMANN-LA ROCHES | 2004-11-16 | — | — | US | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | KCNH2 4150/4885MAPT 3023/4885CRHBP 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.